Scarica l'app Stockscreener
0.3869
2.14%
0.0081
Sangamo Therapeutics Inc Borsa (SGMO) Ultime notizie
How liquid is Sangamo Therapeutics Inc. stockExit Point & Smart Investment Allocation Tips - mfd.ru
Is Sangamo Therapeutics Inc. stock a hidden gem2025 Trading Recap & Consistent Profit Focused Trading Strategies - mfd.ru
Is Sangamo Therapeutics Inc. benefiting from innovation trendsWeekly Investment Report & Expert Verified Movement Alerts - mfd.ru
FY2030 Earnings Forecast for SGMO Issued By HC Wainwright - MarketBeat
Sangamo Therapeutics' (SGMO) Buy Rating Reiterated at HC Wainwright - MarketBeat
SGMO: HC Wainwright & Co. Maintains Buy Rating with $10 PT | SGM - GuruFocus
Assessing Sangamo Therapeutics (SGMO) Valuation After New Fabry Data Financing Move And Leadership Changes - simplywall.st
Sangamo starts FDA submission seeking approval of Fabry gene therapy - Fabry Disease News
Sangamo prices $25 million offering of common stock and warrants By Investing.com - Investing.com Nigeria
What Sangamo Therapeutics (SGMO)'s Fabry Gene Therapy Progress And Equity Raise Means For Shareholders - Sahm
Sangamo Biosciences launches dilutive February 2026 financing - TipRanks
Sangamo Therapeutics Signs Multiple Material Agreements - TradingView
Form 424B5 SANGAMO THERAPEUTICS, - StreetInsider
Sangamo To Present Positive Study Data Of ST-920 In Fabry Disease At WORLD Symposium 2026 - Nasdaq
Should FDA Accelerated Approval Pathway for ST-920 Gene Therapy Data Require Action From Sangamo Therapeutics (SGMO) Investors? - Yahoo Finance
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026 - The Manila Times
Sangamo (SGMO) Appoints Interim CFO Amid Leadership Change - GuruFocus
Sangamo Therapeutics (SGMO) Price Target Increased by 17.31% to 3.89 - Nasdaq
Sangamo gene therapy shows positive kidney function results in Fabry disease - Investing.com India
Sangamo gene therapy shows positive kidney function results in Fabry disease By Investing.com - Investing.com South Africa
One-time Fabry gene therapy lifts kidney function in early trial data - Stock Titan
Sangamo Shares Fall After Pricing $25 Million Public Offering - marketscreener.com
Sangamo Therapeutics (SGMO) Stock Plummets 28% After $25M Offeri - GuruFocus
Sangamo stock plunges after pricing $25 million dilutive offering By Investing.com - Investing.com India
Sangamo Prices $250 Mln Offering; Stock Plunges - Nasdaq
Sangamo stock plunges after pricing $25 million dilutive offering - Investing.com
Sangamo plunges after pricing stock offering; principal financial officer exits - Seeking Alpha
Sangamo Therapeutics reports preliminary cash balance and CFO transition By Investing.com - Investing.com Nigeria
Sangamo Therapeutics to Raise $25 Million Through Public Offering of Common Stock - geneonline.com
Sangamo Therapeutics IncOn Feb 2, Prathyusha Duraibabu terminated as principal financial officerSEC filing - marketscreener.com
Sangamo (SGMO) Appoints Nikunj Jain as Interim CFO - GuruFocus
Sangamo (SGMO) Announces New Stock Offering to Raise $25M - GuruFocus
Sangamo (SGMO) Reports Estimated Year-End Cash Holdings - GuruFocus
Sangamo Therapeutics slides after $25 million stock sale - TradingView
Sangamo Therapeutics Prices Underwritten Offering of Common Stock and Warrants, Expected to Raise Approximately $25 Million - Quiver Quantitative
Sangamo prices $25 million offering of common stock and warrants - Investing.com
Sangamo Therapeutics reports preliminary cash balance and CFO transition - Investing.com
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering - The Manila Times
Improved Revenues Required Before Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Stock's 29% Jump Looks Justified - 富途牛牛
Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Boosted 29% But Its Business Prospects Need A Lift Too - simplywall.st
Analysts Expect Breakeven For Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Before Long - 富途牛牛
Sangamo Therapeutics (NASDAQ:SGMO) Downgraded by Wall Street Zen to Strong Sell - MarketBeat
Dow Update: Is Sangamo Therapeutics Inc a strong growth stock2025 Market WrapUp & Long Hold Capital Preservation Tips - baoquankhu1.vn
How The Pulled Price Target Is Reshaping The Story For Sangamo Therapeutics (SGMO) - Yahoo Finance
Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends - GlobeNewswire Inc.
Aug Selloffs: Does Sangamo Therapeutics Inc have a sustainable dividendWeekly Stock Analysis & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Insider Sell: Whats the outlook for FRSXs sectorWeekly Market Summary & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Does Sangamo Therapeutics Inc. have pricing powerEntry Point & Low Drawdown Momentum Trade Ideas - bollywoodhelpline.com
Published on: 2026-01-14 05:13:16 - Bộ Nội Vụ
Fabry Disease Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics - Barchart.com
Sangamo Therapeutics (SGMO) Shares Stabilize Amid Recent Key Pipeline Update - Finviz
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):